Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Syndecans and the lymphoid system.

L Kopper1, A Sebestyén

  • 11st Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Budapest, Hungary. kopper@korb1.sote.hu

Leukemia & Lymphoma
|June 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of left-sided prosthetic valve endocarditis by suppressive antibiotic therapy: A retrospective monocentric real-world study.

Infectious diseases now·2025
Same author

[Management of Stent-graft migration with obstruction of supra-aortic vessel during an endovascular procedure for aortic isthmus rupture].

Annales de cardiologie et d'angeiologie·2023
Same author

[Constrictive pericarditis and disseminated nocardiosis].

Annales de cardiologie et d'angeiologie·2023
Same author

Early postoperative bleeding after isolated coronary bypasses: Changes over a period of 20 years - An observational study.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2021
Same author

Frequency of Outpatient Physiotherapy Services in Neurology Diseases in Hungary.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Annual Health Insurance Cost of Breast Cancer Treatment in Hungary.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Syndecan-1, a key proteoglycan, is crucial for certain non-Hodgkin lymphomas (NHLs) by mediating cell interactions. Its expression is a valuable diagnostic marker for plasmacytic differentiation in lymphomas.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Immunology

Background:

  • Syndecans are transmembrane proteoglycans involved in cell adhesion and signaling.
  • Syndecan-1, specifically, has roles in cell-matrix and cell-cell interactions.
  • Its expression pattern varies across hematopoietic cell types and differentiation stages.

Purpose of the Study:

  • To investigate the expression of syndecan-1 in various lymphoproliferative conditions.
  • To determine the diagnostic utility of syndecan-1 as a phenotypic marker.
  • To understand the role of syndecan-1 in the microenvironment of certain lymphomas.

Main Methods:

  • Immunohistochemical analysis of syndecan-1 expression in lymphoma tissues.
  • Correlation of syndecan-1 expression with specific lymphoma subtypes and differentiation stages.

Related Experiment Videos

  • Comparative analysis of syndecan-1 expression in normal hematopoietic cells and malignant lymphocytes.

    • Main Results:

    • Syndecan-1 is selectively expressed in B cells during specific differentiation stages (pre-B, plasma cells).
    • This selective expression is maintained in myelomas, plasmacytomas, lymphoplasmacytic NHLs, and primary effusional lymphomas.
    • Syndecan-1 expression may be gained in B-cell chronic lymphocytic leukemia (B-CLL) and lost in other NHLs.
    • Syndecan-1 appears essential for the microenvironmental interactions of some NHLs.

    Conclusions:

    • Syndecan-1 expression is a significant indicator of plasmacytic differentiation and is a useful diagnostic marker.
    • The protein's role is essential for the survival and proliferation of certain NHLs by facilitating microenvironmental connections.
    • Further research is needed to elucidate the importance of syndecan expression in CLL and Hodgkin's lymphoma.